One Psychedelic Treatment, Weeks of Relief: Two Clinical Trials Show Promise for People Whose Depression Resisted Multiple Antidepressants

A single psychedelic treatment brought meaningful relief to some people whose depression had resisted several antidepressants. In two randomized clinical trials published in 2026, the short-acting compound 5-MeO-DMT, also called mebufotenin, reduced depressive symptoms after just one treatment session. One trial found benefits lasting through eight weeks after a nasal spray; another reported striking remission rates eight days after inhalation. Unlike conventional antidepressants taken daily, the experimental treatment was given under medical supervision with psychological support.

One treatment after several antidepressants had failed

Treatment-resistant depression is more than a difficult week or a temporary low mood. Participants in both trials had moderate to severe major depressive disorder and had not responded adequately to two to five previous antidepressant treatments during their current episode. This matters: the researchers were studying people for whom standard medication had already been disappointing.

In the newer trial, published in JAMA in October 2026, 193 adults across 38 sites received one intranasal dose of mebufotenin or a very low comparator dose, together with psychological support. After 29 days, depression scores fell by 11.1 points with the 12-mg dose and 12.5 points with the 8-mg dose, compared with 5.5 points in the low-dose group. The adjusted advantage over the comparator was 5.3 and 6.2 points, respectively, on a 60-point clinician-rated depression scale.

About 34% to 35% of people receiving an active dose achieved a substantial symptom response by day 29, compared with 12% in the low-dose group. Remission, meaning symptoms dropped below a defined clinical threshold, occurred in 18% to 26%, compared with 8%. Depression scores remained significantly better than the comparator through day 57. These results are promising precisely because the benefit followed a single administration, not weeks of repeated dosing.

An inhaled version produced an even faster signal

An earlier randomized trial, published in JAMA Psychiatry in March 2026, studied 81 adults with treatment-resistant depression. Forty received individualized inhaled mebufotenin, called GH001, during a single treatment day; 41 received placebo. By day eight, 57.5% of the treated participants were in remission, versus none in the placebo group. Depression scores also improved more in the treated group.

The two findings are complementary, not interchangeable. Inhaled GH001 and intranasal BPL-003 use the same psychedelic molecule, but different formulations, dosing strategies, controls and assessment days. The 57.5% and 26% remission figures do not establish that inhalation is superior to nasal delivery. Nor does an eight-day placebo-controlled result prove that one inhalation provides months of relief. The GH001 trial continued with an open-label follow-up in which some patients received additional treatments, so its longer-term findings cannot be interpreted as a single-dose placebo-controlled effect.

Together, however, these independent phase 2b development programs strengthen the case that short-acting 5-MeO-DMT deserves larger clinical trials for difficult-to-treat depression.

Why a brief psychedelic experience could matter

Psilocybin-assisted treatment may involve several hours of acute psychedelic effects and extended clinical monitoring. Mebufotenin acts much more briefly, which could make supervised treatment easier to provide if future trials confirm its benefits and safety. In the nasal-spray study, 78% to 85% of active-dose participants were deemed ready for discharge within two hours after dosing. This was a readiness assessment, not a claim that clinical sessions or psychological support lasted only two hours.

The key question is whether a brief, intensely altered state can be followed by a much longer antidepressant response. Researchers are investigating serotonin-receptor signaling and downstream changes in brain networks, but these trials did not establish which biological or psychological processes produced the benefits. This is not an at-home nasal spray: the investigational treatments were administered by trained clinical teams in controlled settings.

The study results also show why the condition remains challenging. Most actively treated patients in the nasal-spray trial did not reach the formal response threshold by day 29. Adverse events were common, mostly mild or moderate, and the possibility of participants recognizing their active treatment complicates interpretation. Both trials were phase 2b, and larger phase 3 studies are needed before regulatory approval or routine clinical use.

What can people do while new treatments are being tested?

People living with persistent depression do not need to wait for psychedelic research to move forward before exploring established options with a clinician. Depending on the individual, these can include optimizing existing medication, evidence-based psychotherapy, and specialist treatments for difficult-to-treat depression. The new mebufotenin findings should add another possible future option, not displace care that is available today.

For readers exploring complementary approaches, standardized saffron extract has also been studied in randomized trials. A 2026 synthesis of 34 trials found improvements in self-reported depression scores, but not consistently in clinician-rated depression outcomes. It is not an established treatment for treatment-resistant depression and should not replace prescribed care; anyone considering it alongside antidepressants should discuss safety and interactions with their clinician.

What makes the 2026 mebufotenin research important is the possibility of a supervised treatment that takes hours rather than repeated daily doses, yet delivers measurable benefits weeks later. For people who have already tried several antidepressants without sufficient relief, that is a direction worth investigating carefully.

Scientific References & Further Reading

• Anchor Study: “Feifel et al. Intranasal mebufotenin for treatment-resistant depression.” (JAMA. 2026. doi:10.1001/jama.2026.18380.)
• Related Randomized Trial: “Cubała et al. GH001 vs Placebo in Patients With Treatment-Resistant Depression.” (JAMA Psychiatry. 2026. doi:10.1001/jamapsychiatry.2026.0096.)
• Supplement Evidence: “Mahmoudi et al. Effect of saffron on depression, anxiety and mood disorder.” (Nutr Neurosci. 2026. doi:10.1080/1028415X.2025.2602153.)

---

Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not a substitute for diagnosis, treatment, or individualized medical care.